



MassHealth Coverage Update, Starting July 1, 2026: Anti-Obesity Drugs

June 2026 | Our Products | Commonwealth Care Alliance® (CCA)

Starting July 1, 2026, CCA ends its coverage of some weight loss drugs. Members with Commonwealth Care Alliance® Senior Care Options (HMO D-SNP) are affected. This change aligns with MassHealth rules for anti-obesity drugs.

No Longer Covered for Weight Loss:

- Benzphetamine
- Diethylpropion and diethylpropion extended-release
- Saxenda (liraglutide)
- Xenical (orlistat)
- Phendimetrazine and phendimetrazine extended-release
- Lomaira and Adipex-P (phentermine capsules and tablets)
- Contrave (bupropion/naltrexone)
- Qsymia (phentermine/topiramate)
- Wegovy (semaglutide)
- Zepbound (tirzepatide)

More Information

Members given GLP-1 drugs for weight loss are impacted; other coverage for Medicare approved GLP-1 drugs and indications remain the same.

CCA Senior Care Options members have access to GLP-1 drugs for weight loss through the CMS BRIDGE program as of July 1, 2026. The BRIDGE program requires members cover a \$50 co-pay. CCA is not responsible for the \$50 co-pay.

Visit [Medicare GLP-1 Bridge | CMS](#) for details on BRIDGE.

H2225_MA-SNP-M-5783551_C